Ultralow dose pet scan for certain tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a new way to take PET scan pictures using a very low amount of a radioactive tracer that targets a protein called SSTR2. It is designed to see if these scans can work well while reducing radiation exposure for patients with certain types of tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You can understand study procedures and agree to take part.
- If you are a woman who can get pregnant, you are not pregnant or breastfeeding, and you have a negative pregnancy test.
- You have not already had too much radiation from other research scans (total under 50 millisieverts).
- You have not taken any treatments that target SSTR2.
- You do not have severe claustrophobia, chronic pain, or other conditions that stop you from staying still for the scan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new way to take brain imaging scans (PET scans) using a very small amount of radioactive tracer. Researchers want to see if they can get clear pictures of your brain while reducing your radiation exposure compared to standard scans.
This study tests if a very low dose of a standard PET scan tracer (FDG) can produce clear images. It may help people who need a PET scan but are concerned about radiation exposure.
This trial tests a very low dose of a radioactive tracer (18F-flurpiridaz) for PET scans of the heart. It aims to see if using less radiation still produces clear images, which may be safer for patients who need repeated scans.
This study tests a very low-dose PET scan to see if it can find prostate cancer cells that have PSMA on their surface. It might help you avoid higher radiation doses while still getting important images.
This study uses a special type of PET scan (called SSTR PET/CT) to look at tumors that may have a specific receptor. The scan helps doctors see where these tumors are and how active they are.
This pilot study tests a total-body PET scan with approved tracer medicines to help detect cancer spread in people with suspected metastatic prostate cancer or certain neuroendocrine tumors (NETs). You may be able to join if recent scans already suggest metastasis and you can safely complete the scan timing and positioning.
Hear when a new Neuroendocrine (NE) Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.